{"id":"W2243412420","doi":"10.1200/jco.2013.31.15_suppl.2574","title":"Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma (B-NHL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Gastroenterology; Neutropenia; Rituximab; Internal medicine; Calicheamicin; Febrile neutropenia; Toxicity; Lymphoma; Gemcitabine; Regimen; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000824758,0.00112382,0.001760828,0.000395993,0.0003666518,0.0009167032,0.0009397057,0.0009555065,0.002549315],"category_scores_gemma":[0.000503387,0.0006036857,0.0008898511,0.0003471227,0.0008273642,0.0006561508,0.0003561119,0.002613029,0.0008040166],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008965958,"about_ca_system_score_gemma":0.001631587,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001136382,"about_ca_topic_score_gemma":0.00286835,"domain_scores_codex":[0.9997262,0.0001207239,0.00001314934,0.00004795165,0.00002383806,0.00006815264],"domain_scores_gemma":[0.9996098,0.00004322776,0.00005830382,0.0000424862,0.00002162917,0.0002245705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5401906,0.1790762,0.008466732,0.001411323,0.002214902,0.000630278,0.0005341485,0.004461756,0.1146179,0.0006939733,0.006133707,0.1415684],"study_design_scores_gemma":[0.3394334,0.6366795,0.009494497,0.00004642608,0.0007038576,0.0003593025,0.00007160181,0.001363345,0.007246274,0.0001969836,0.004379203,0.00002572496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924684,0.001539228,0.0005599443,0.0002687267,0.0001322576,0.002643585,0.0006411588,0.0001002043,0.001646457],"genre_scores_gemma":[0.9911311,0.001648751,0.001281977,0.0004910562,0.000115589,0.002127046,0.001326035,0.00002652377,0.001851946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002549315,"threshold_uncertainty_score":0.008528352,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07489875581887857,"score_gpt":0.4337416432493884,"score_spread":0.3588428874305098,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}